These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 11326821)

  • 1. Association between tuberculosis and HIV disease progression in a high tuberculosis prevalence area.
    Badri M; Ehrlich R; Wood R; Pulerwitz T; Maartens G
    Int J Tuberc Lung Dis; 2001 Mar; 5(3):225-32. PubMed ID: 11326821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of tuberculosis on the course of HIV-infected patients with a high initial CD4 lymphocyte count.
    Mañas E; Pulido F; Peña JM; Rubio R; Gonzalez-García J; Costa R; Pérez-Rodríguez E; Del Palacio A
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):451-7. PubMed ID: 15141738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
    HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-associated extrapulmonary tuberculosis in Thailand: epidemiology and risk factors for death.
    Kingkaew N; Sangtong B; Amnuaiphon W; Jongpaibulpatana J; Mankatittham W; Akksilp S; Sirinak C; Nateniyom S; Burapat C; Kittikraisak W; Monkongdee P; Varma JK
    Int J Infect Dis; 2009 Nov; 13(6):722-9. PubMed ID: 19196530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 co-infection in children hospitalised with tuberculosis in South Africa.
    Madhi SA; Huebner RE; Doedens L; Aduc T; Wesley D; Cooper PA
    Int J Tuberc Lung Dis; 2000 May; 4(5):448-54. PubMed ID: 10815739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.
    Seyler C; Toure S; Messou E; Bonard D; Gabillard D; Anglaret X
    Am J Respir Crit Care Med; 2005 Jul; 172(1):123-7. PubMed ID: 15805184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of tuberculosis in HIV-infected patients receiving HAART: interaction between TST and CD4 count.
    Martín-Echevarria E; Rodríguez-Zapata M; Torralba M; Fernández JM; Moreno A; Casado JL; Dronda F; Pérez-Elías MJ; Navas E; Moreno S
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1347-52. PubMed ID: 22283893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
    Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
    J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
    El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
    AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of HIV-infected tuberculosis patients in Thailand.
    Mankatittham W; Likanonsakul S; Thawornwan U; Kongsanan P; Kittikraisak W; Burapat C; Akksilp S; Sattayawuthipong W; Srinak C; Nateniyom S; Tasaneeyapan T; Varma JK
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):93-103. PubMed ID: 19323040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early participation in an HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study.
    Battegay M; Wirz M; Steuerwald MH; Egger M
    J Intern Med; 1998 Dec; 244(6):479-87. PubMed ID: 9893101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study.
    Hershow RC; O'Driscoll PT; Handelsman E; Pitt J; Hillyer G; Serchuck L; Lu M; Chen KT; Yawetz S; Pacheco S; Davenny K; Adeniyi-Jones S; Thomas DL
    Clin Infect Dis; 2005 Mar; 40(6):859-67. PubMed ID: 15736020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in a cohort of human immunodeficiency virus-infected tuberculosis patients in New York City. Implications for the expansion of the AIDS case definition.
    Stoneburner R; Laroche E; Prevots R; Singh T; Blum S; Terry P; Reatrice S; Adler J
    Arch Intern Med; 1992 Oct; 152(10):2033-7. PubMed ID: 1358042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.